Supriya Lifescience IPO: Information analysis

Starting its journey as a partnership firm in 1985, Supriya Lifescience became a full-fledged company in 2008. Involved in manufacturing and supplying active pharmaceutical ingredients (APIs), the company caters to niche therapeutic segments, such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and so on. As of October 2021, the company had 38 APIs, with 12 of them having backward integration and contributing 67 per cent to its FY21 revenue. Located in Maharashtra, its manufacturing facility has a capacity of 547 kilolitres per day. Besides, the company has acquired a plot to expand its operations. Thanks to its strong international presence, the company exports its products to over 86 countries, comprising Europe (17.4 per cent of FY21 revenue) Latin America (19.2 per cent), other Asian countries (29.3 per cent) and North America (4.8 per cent). Overall, exports accounted for 77.5 per cent of its FY21 revenue. On the other hand, India contributed 22.5 per cent to th